Author

J. DeMartino

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:scRNA-seq· 2 Research Focus:cell-cell communication· 1 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

J. Drost· 2 shared J. J. Molenaar· 2 shared L. S. Hiemcke-Jiwa· 2 shared M. Brok· 2 shared M. J. A. Groot Koerkamp· 2 shared M. T. Meister· 2 shared M. van de Wetering· 2 shared S. Eising· 2 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Drost

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Multi-dimensional profiling of hepatoblastomas and patient-derived tumor organoids uncovers tumor subpopulations with divergent WNT activation profiles and identifies pan-hepatoblastoma drug sensitivities

T. A. Kluiver, Y. Lu, S. A. Schubert, L. J. Kraaier, F. Ringnalda, P. Lijnzaad, J. DeMartino, W. L. Megchelenbrink, V. Amo-Addae, S. Eising, F. W. de Faria, D. J. Munter, M. van de Wetering, K. Kerl, E. Duiker, , W. C. Peng

This study identifies two hepatoblastoma subtypes with distinct WNT activation profiles and discovers drug sensitivities in patient-derived tumor organoids.

bioRxiv · Aug 28, 2023 · PreprintCancer Biology

Single-cell transcriptomics reveals immune suppression and cell states predictive of patient outcomes in rhabdomyosarcoma.

J. DeMartino, M. T. Meister, L. Visser, M. Brok, M. J. A. Groot Koerkamp, L. S. Hiemcke-Jiwa, T. de Souza, J. Merks, F. C. Holstege, T. Margaritis, J. Drost

This study uses single-cell transcriptomics to identify immune suppression and cell states in rhabdomyosarcoma that predict patient outcomes.

bioRxiv · Jul 15, 2022 · PreprintCancer Biology

Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes

M. T. Meister, M. J. A. Groot Koerkamp, T. de Souza, W. B. Breunis, E. Frazer-Mendelewska, M. Brok, J. DeMartino, F. Manders, C. Calandrini, H. H. D. Kerstens, A. Janse, M. E. M. Dolman, S. Eising, K. P. S. Langenberg, M. van Tuil, , F. C. P. Holstege

This study generates tumor organoid models of rhabdomyosarcoma subtypes that closely resemble original tumors and can be used for drug screening and genetic modification.

bioRxiv · Jan 3, 2022Cancer Biology